XMAB23104

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

XMAB23104 is an experimental medication currently being studied in clinical trials for certain types of advanced solid tumors, including colorectal cancer. It is being investigated as a potential treatment option, often in combination with other therapies like ipilimumab. The trials involving XMAB23104 in colorectal cancer have been in Phase 1, which means they are primarily focused on determining the safest dose and understanding how the drug is processed by the body (pharmacokinetics) and how the immune system reacts to it (immunogenicity). These early trials also look for early signs of whether the drug might shrink tumors or slow their growth. The trials have included patients with microsatellite stable (MSS) tumors and those whose tumors do not express high levels of HER2.

Mechanism of Action

XMAB23104 is an experimental medication. The specific way it works (its mechanism of action) is still being investigated in clinical trials. It is designed to interact with the body's immune system, potentially helping it to recognize and attack cancer cells. It is being studied both on its own (monotherapy) and in combination with ipilimumab, another immunotherapy drug.

Side Effects

Because XMAB23104 is still in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. Information from the NCT03752398 trial indicates that the study aims to assess the safety and tolerability of XMAB23104. Specific side effects observed in these early trials are not detailed in the provided information But as with many cancer treatments Potential side effects could include immune-related adverse events Fatigue Skin reactions Gastrointestinal issues And others. Patients participating in clinical trials are closely monitored for any side effects.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03752398 Phase 1
Archived
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
787 trials
Leucovorin
Other Medications
648 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.